Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

Cerivastatin, an HMG-CoA reductase inhibitor withdrawn from the market due to serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics due to gemfibrozil-inhibition or genetic var...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kaspera, Rüdiger, Naraharisetti, Suresh B., Tamraz, Bani, Sahele, Tariku, Cheesman, Matthew J., Kwok, Pui-Yan, Marciante, Kristin, Heckbert, Susan R., Psaty, Bruce M., Totah, Rheem A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993694/
https://ncbi.nlm.nih.gov/pubmed/20739906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0b013e32833ecace
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg